In review of CRISPR patent interference, US panel says board legally erred
MLex Summary: A determination of priority by the Patent Trial and Appeal Board in interference proceedings between an issued patent and a patent application directed to CRISPR-Cas9 gene editing must be...To view the full article, register now.
Already a subscriber? Click here to view full article